|
| related topics |
| {product, candidate, development} |
| {system, service, information} |
| {product, liability, claim} |
| {operation, international, foreign} |
| {customer, product, revenue} |
| {regulation, government, change} |
| {condition, economic, financial} |
| {financial, litigation, operation} |
| {acquisition, growth, future} |
|
|
The Company faces intense competition from other pharmaceutical manufacturers, including from lower-priced generic products.
The Company depends on key products for most of its net sales, cash flows and earnings.
It is possible that the Company may lose market exclusivity of a product earlier than expected.
Data protection for PLAVIX* has expired in the EU and PLAVIX* faces competition in European markets.
U.S. and foreign laws and regulations may negatively affect the Company s sales and profit margins.
The Company faces increased pricing pressure in the U.S. and abroad from managed care organizations, institutional purchasers, and government agencies and programs that could negatively affect the Company s sales and profit margins.
The Company may experience difficulties and delays in the manufacturing and sale of its products.
The Company may experience difficulties or delays in the development and commercialization of new products.
There are legal matters in which adverse outcomes could negatively affect the Company s business.
The Company relies on third parties to meet their contractual, regulatory, and other obligations.
Failure to execute the Company s business strategy could adversely impact its growth and profitability.
The Company is increasingly dependent on its information technology and outsourcing arrangements.
Recent adverse changes in U.S., global, or regional economic conditions could have a continuing adverse effect on the profitability of some or all of our businesses.
Changes in foreign currency exchange rates and interest rates could have a material adverse effect on our results of operations.
The illegal distribution and sale by third parties of counterfeit versions of the Company s products could have a negative impact on our reputation.
Full 10-K form ▸
|
|
| related documents |
| 14272--2/22/2008--BRISTOL_MYERS_SQUIBB_CO |
| 14272--2/19/2010--BRISTOL_MYERS_SQUIBB_CO |
| 38074--6/14/2006--FOREST_LABORATORIES_INC |
| 38074--5/30/2008--FOREST_LABORATORIES_INC |
| 38074--5/30/2007--FOREST_LABORATORIES_INC |
| 1000694--3/6/2006--NOVAVAX_INC |
| 1062822--3/12/2007--LEXICON_GENETICS_INC/TX |
| 858803--12/18/2006--AVANIR_PHARMACEUTICALS |
| 926763--3/16/2007--ASV_INC_/MN/ |
| 1123361--3/6/2007--VIASYS_HEALTHCARE_INC |
| 1123361--3/14/2006--VIASYS_HEALTHCARE_INC |
| 810509--3/31/2008--NEOPROBE_CORP |
| 926763--3/16/2006--ASV_INC_/MN/ |
| 914475--2/7/2006--NEUROCRINE_BIOSCIENCES_INC |
| 310158--2/28/2006--SCHERING_PLOUGH_CORP |
| 858803--12/17/2008--AVANIR_PHARMACEUTICALS |
| 943736--3/31/2006--MED-DESIGN_CORP |
| 1020214--3/11/2010--CERUS_CORP |
| 1020214--2/26/2007--CERUS_CORP |
| 858803--12/21/2007--AVANIR_PHARMACEUTICALS |
| 897075--3/17/2008--REPROS_THERAPEUTICS_INC. |
| 310158--2/28/2007--SCHERING_PLOUGH_CORP |
| 816284--2/17/2009--CELGENE_CORP_/DE/ |
| 64978--2/27/2009--MERCK_&_CO_INC |
| 1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO |
| 897075--3/16/2009--REPROS_THERAPEUTICS_INC. |
| 1096560--4/2/2007--SULPHCO_INC |
| 1041859--4/12/2006--CHILDRENS_PLACE_RETAIL_STORES_INC |
| 881890--6/14/2010--ABAXIS_INC |
| 23259--3/31/2006--CT_COMMUNICATIONS_INC_/NC |
|